self: /index.php
request:
Notice: Undefined index: uri in /var/www/www2/rdsfund.com/http/www/templates_c/8bc0e9658f2b7f61bb9a1da346fcc22d916b4557_0.file.layout.tpl.php on line 55

Notice: Trying to get property of non-object in /var/www/www2/rdsfund.com/http/www/templates_c/8bc0e9658f2b7f61bb9a1da346fcc22d916b4557_0.file.layout.tpl.php on line 55
title: RDS Fund
router: 
Notice: Undefined index: router in /var/www/www2/rdsfund.com/http/www/templates_c/8bc0e9658f2b7f61bb9a1da346fcc22d916b4557_0.file.layout.tpl.php on line 59

Notice: Trying to get property of non-object in /var/www/www2/rdsfund.com/http/www/templates_c/8bc0e9658f2b7f61bb9a1da346fcc22d916b4557_0.file.layout.tpl.php on line 59
NULL
siteData: 
Notice: Undefined index: siteData in /var/www/www2/rdsfund.com/http/www/templates_c/8bc0e9658f2b7f61bb9a1da346fcc22d916b4557_0.file.layout.tpl.php on line 61

Notice: Trying to get property of non-object in /var/www/www2/rdsfund.com/http/www/templates_c/8bc0e9658f2b7f61bb9a1da346fcc22d916b4557_0.file.layout.tpl.php on line 61
NULL
session: array (
  'lang' => '',
)
Unia Europejska, Europejski Fundusz Rozwoju Regionalnego

BRIdge Alfa

The investment objective of the Project is to establish, incubate and prepare for foreign expansion and subsequent / subsequent financing rounds, 26 motivated to further development, innovative capital companies based on at least two-person teams composed of: "entrepreneur" and "hacker" technologist - possessing global development potential.

We aim to find and implement projects with the highest development potential due to its global reach. Our companies are to achieve readiness to absorb subsequent rounds of capital financing within 12-18 months.

The total value of funds managed by the Manager (RDS Fund Sp z o.o.) including the amount of the subsidy from the National Center for Research and Development is PLN 49,577,200, including the amount of the subsidy from the National Center for Research and Development 39,395,000 PLN, amount paid by private investors PLN 10,217,200. Ultimately, the funds involved in the Portfolio amount to PLN 41 million (acquisition of shares plus subsidies), of which PLN 8.2 million is the expenditure of ASI (ASI RDS Fund limited liability company limited partnership) for the acquisition of shares in Portfel companies.

Project co-financed / financed by the National Center for Research and Development under the program BridgeAlfa.

Submit an idea

rozpocznij
globalna perspektywa
rdsfund-zespol

First Polish Medicine

The specific object of the Fund's investment, related to the rapidly growing and very promising market area of strategic importance for the security of Poland and the region.

Global perspective

Independent international experts and industry partners operating on a global scale help the RDS Fund team in choosing the best development and commercialization scenario for each company.

Team

Suitable in terms of competence and experience (and in connection with investment specialization), as well as the determined team of RDS Fund Sp. z o.o. (the team has invested over PLN 100 million).

Unique Polish IP

Investing in ventures based on the Polish IP unique in the world, created and identified in cooperation with leading national universities and scientific institutions, increasing the likelihood of market success (also on a global scale) of financed ventures.

Exit strategy

The team's experience and cooperation of RDS Fund with investors of various investment profiles makes it easier to prepare projects for obtaining from the market next rounds of financing, commercialization and exit of the Fund from investment.

Investment process

A well-thought-out and well-structured investment process in the Proof-of-Principle and Proof-of-Concept phases as well as a reasonable project budget, providing adequate commitment at every stage of financing.

Submit an idea

What do we invest in?

Innowacyjne rozwiązania

Innovative solutions, research and development element, advanced technologies, unique IP, global potential.

Chemical and biological medicinal products, biotechnology, new technologies (ATMP, HE); Medical devices, dietary supplements, functional foods - for special medical purposes;

e-Medicine, Internet of Things, Cybersecurity and in particular:

  • Telemedicine safety

    solutions ensuring secure storage of tele-medical / metric data and their secure transmission to relevant services,

  • Telemedicine safety

    solutions ensuring secure storage of tele-medical / metric data and their secure transmission to relevant services,

Submit an idea

Investment criteria

Kryteria inwestycji

Investment criteria

  • forward-looking ideas / undertakings as to the possibility of their commercialization, based on positive verification of market demand,
  • projects under which new products and services will be developed, which are characterized by a high level of innovation and uniqueness, resulting from the results of research and development works carried out,
  • new products and services with global potential,
  • financed projects are scalable,
  • IP assets of financed projects may be subject to effective legal protection or they may be effectively secured as know-how,
  • a dedicated team with appropriate competences and very high determination as to the implementation of the financed project.
  • Submit an idea
  • If you are convinced that your solution will change the world, please. Call us or write to e-mail.
  • Fill in the form or download word, fill out and send to our email: info / at / rdsfund.com
Kryteria inwestycji

Our partners

About us

Roman Kosiński

Roman Kosiński

Chairman of the Investment Committee

Over 30 years of investment experience, director of the BRE SA brokerage office (currently MBANK), director of capital investments at Bankowe Towarzystwo Kapitałowe SA, member of the board of Zakłady Tytoniowe Lublin SA, president of the board of Towarzystwo Funduszy Inwestycyjnych KORONA SA, President of the Management Board of Towarzystwo Funduszy Inwestycyjnych WARTA SA, adviser to the President of the National Bank of Poland, adviser to the President of PKO BP, supervisory boards, including the 12th National Investment Fund PIAST SA, Wedel SA, Próchnik SA

Krzysztof Nowański

Krzysztof Nowański

Vice-chairman of the Investment Committee

Entrepreneur and seed investor. He specializes in issues related to security and telemedicine. Alone, as part of the Innovation Factory or as part of the Business Angels Network, Protech AB invested and co-created the following projects: Eversys - data leakage protection, Voxtrack BS - recording of mobile conversations, Safekiddo - parental control, BonEffice - "electronic fuel injection" in power blocks, Crowley Media Poland - the successor of online television for citizen journalism. A graduate of the Warsaw University of Technology, the faculty of electronics. MBA - Warsaw University of Technology Business School and London Business School.

Prof. dr hab. n. med. Piotr Fiedor

Prof. dr hab. n. med. Piotr Fiedor

Key Staff

Over 25 years of experience in the implementation of research and clinical programs in the field of new medical technologies and advanced therapies in clinical transplantology in Poland and the USA. Member of the Committee for Medicinal Products at the Office for Registration of Medicinal Products (Poland). The Polish delegate at the European Medicines Agency, a member of the ICPerMed Executive Committee, has completed the registration process for over 100 drugs at the level of the European Medical Agency as a regulator and company, head of the Drug Control Department and Chairman of the Bioethics Committee of the Medicines Institute in Warsaw, Polish representative in nCADREAC (cooperation agreement between drug control authorities in the countries associated with the European Union), a member of the American Society of Transplantation (ASTS - American Society of Transplant Surgeons), Head of the Laboratory of Advanced Therapies at the Medical University of Warsaw. Implementation of the first biotechnology product in Poland called Gensulin (recombinant human insulin, currently Bioton SA). Implementation of the Instrument for light coagulation - a device for clinical purposes of stopping bleeding during surgery on parenchymal organs, commercialized and used in surgery, urology and gynecology in Poland.

Andrzej Zackiewicz

Andrzej Zackiewicz

Key Staff, Investment Committee

MSc. Technical Physics - Warsaw University of Technology, holds an MBA title jointly awarded by the London Business School and the Warsaw School of Business. An experienced financier, entrepreneur and investor, he has extensive experience in structuring investment transactions. In 2000-2012, as a financial director, he worked for the private Luxembourg investment fund Eastbridge (assets over € 1.5 billion). Since 2013, he has been advising the management board of the "Economic Society Society" Foundation on the management of a portfolio of 27 seed companies. Co-founder of the IEN S.A. Group

Anita Urbaniak

Anita Urbaniak

Key Staff

An experienced financial director, R&D project manager, associated with the Crowley Group since 2006. Since 2008, he has been involved in acquiring and managing the Group's investment projects. Has over 8 years of experience in the financing and management of R&D projects in the PoP and PoC phases.